RNRMarketResearch.com

European Radiopharmaceuticals Market Forecast to 2017 and Competitive Landscape

Press Release   •   Sep 17, 2014 06:41 EDT

Analysis and discussion about radiopharmaceuticals market, its forecasts and more is now available in the global research report “European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017”. This report is of 302 pages and can be ordered at ReportsnReports.com.

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 83% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by Thallium–201(Tl-201), Gallium–67 (Ga-67) and Iodine-123 (I-123). SPECT is majorly used in cardiology related diagnosis; it is poised to grow at a CAGR of 7.0% from 2012 to 2017. The PET radioisotopes market is dominated by Fluoride-18 (F-18), followed by Rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by Iodine–131(I-131), which is poised to grow at a CAGR of 3.9% from 2012 to 2017. European market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin’s lymphoma. Significant isotopes in the brachytherapy market are Cesium-131 (Cs-131), Iodine-125 (I-125), Palladium-103 (Pd-103), and Iridium-192 (Ir-192). German is the major market for brachytherapy in terms of market share, followed by France. However, this market is showing slow growth due to reimbursement issues.

Complete report available at http://www.reportsnreports.com/reports/232685-european-nuclear-medicine-radiopharmaceuticals-market-spect-pet-radioisotopes-technetium-f-18-beta-alpha-radiation-therapy-i131-y-90-applications-cancer-oncology-cardiac-stable-isotopes-deuterium-c-13-global-trends-forecast-to-2017.html .

European stable isotopes market is dominated by Deuterium (D2), Oxygen-18 (O-18), Carbon-13 (C-13), and Nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The European stable isotopes market was estimated at $24.7 million in 2012 and expected to reach $37.7 million by 2017 at a CAGR of 8.8%.

Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s disease, and dementia are boosting up the European nuclear medicines market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential in the clinical diagnosis and therapeutic applications while the shutdown of NRU in 2016 and OSIRIS in France by 2018 seems to be the major threat for the manufacturers.

Germany is the largest consumer market for radiopharmaceuticals in the Europe.  There are only 5 major reactors in the world and the rest of the countries are completely depend on the productions form those reactors and a few countries such as Poland, Australia, Argentina, and South Africa have started producing Mo-99 at their own reactors.

Major players in the radiopharmaceuticals market are Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany). The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.), and Sigma Aldrich (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Inquire for discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=232685 . (Original Price US $4650 for single user)

List of Figures

Figure 1 Europe: Radiopharmaceuticals Market, By Segment, 2010 – 2017
Figure 2 Europe: Radiopharmaceuticals Market, By Country, 2012 ($Million)
Figure 3 Europe: Stable Isotopes Market, 2012 – 2017 ($Million)
Figure 4 Evolution Of Radiopharmaceuticals
Figure 5 Radiopharmaceuticals Market Segmentation
Figure 6 Enriched Stable Isotopes Market Segmentation
Figure 7 Market Dynamics
Figure 8 European Radiopharmaceuticals: Market Share Analysis, By Key Players, 2012
Figure 9 Germany: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 10 France: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 11 Italy: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 12 Spain: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 13 U.K.: Radiopharmaceuticals Market Share Analysis, By Key Player, 2012
Figure 14 Switzerland: Radiopharmaceuticals Market Share Analysis, By Key Players, 2012
Figure 15 European Enriched Stable Isotope: Market Share Analysis, By Key Players, 2012
Figure 16 Opportunity Matrix: European Diagnostic Radiopharmaceuticals Market (2012)
Figure 17 Spect Radiopharmaceuticals Market Share (2012)
Figure 18 Pet Radiopharmaceuticals Market Share (2012)
Figure 19 Opportunity Matrix: European Therapeutic Radiopharmaceuticals Market (2012)
Figure 20 Ra-223 Decay Chain
Figure 21 Porter’s Five Forces Analysis For Alpharadin
Figure 22 SWOT Analysis Of Alpharadin
Figure 23 Diagnostic Radiopharmaceuticals Market, By Indication (2012)
Figure 24 Key Growth Strategies, 2010 –2013
Figure 25 Cambridge Isotope Laboratories Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Billion)
Figure 26 Cardinal Health, Inc.: Total Revenue, 2010 – 2012 ($Billion)
Figure 27 Covidien, Plc: Radiopharmaceuticals Revenue, 2010 – 2012 ($Million)
Figure 28 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 29 General Electric Company: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 30 IBA Group: Total Market Revenue, 2009 – 2011 ($Million)
Figure 31 Isotec Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 32 Lantheus: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Figure 33 Nordion, Inc.: Total Market Revenue, 2010 – 2012 ($Million)
Figure 34 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 35 Urenco Limited: Total Market Revenue, 2009 – 2011 ($Billion)

Purchase a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=232685 . (This is a premium research report priced at US$ 4650 for single user PDF license).


About Us:

ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. Our research specialists & industry experts, through our market research offerings, ensure we deliver on all your business & industry research requirements - first time and every time!